A Phase 1, Randomized, Double-Blind, Parallel and Placebo-Controlled Single and Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of LIB-01 in Healthy Participants

2023-505280-36-00 Protocol DCT3934 Human pharmacology (Phase I) - First administration to humans Ended

Start 25 Aug 2023 · End 4 Apr 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol DCT3934

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 72
Countries 1
Sites 1

Erectile dysfunction

Key facts

Sponsor
Dicot AB, Dicot AB
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male
Therapeutic area
Diseases [C] - Male Urogenital Diseases [C12]
Trial duration
25 Aug 2023 → 4 Apr 2024
Decision date (initial)
2023-08-14
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Erectile dysfunction

VersionLevelCodeTermSystem organ class
20.0 PT 10061461 Erectile dysfunction 100000004872

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Dicot AB

Sponsor organisation
Dicot AB
Address
S:t Olofsgatan 11a, Uppsala Domkyrkofors. Uppsala Domkyrkofors.
City
Uppsala
Postcode
753 21
Country
Sweden

Scientific contact point

Organisation
Dicot AB
Contact name
Charlotta Gauffin

Public contact point

Organisation
Dicot AB
Contact name
Elin Trampe

Dicot AB

Sponsor organisation
Dicot AB
Address
S:t Olofsgatan 11a, Uppsala Domkyrkofors Uppsala Domkyrkofors
City
Uppsala
Postcode
753 21
Country
Sweden

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Sweden Ended 72 1
Rest of world 0

Investigational sites

Sweden

1 site · Ended
CTC Clinical Trial Consultants AB
CTC Akademiska, Ingang 85 Vaning 2, 751 85, Uppsala

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Sweden 2023-08-25 2024-04-04 2023-08-25

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-05-31 Sweden Acceptable with conditions
2023-08-14
2023-08-14
2 SUBSTANTIAL MODIFICATION SM-1 2023-08-24 Sweden Acceptable
2023-10-05
2023-10-05